Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Recordati Rare Diseases Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner in 1 distinct art unit. NICKOL, GARY B is the busiest examiner, with 1 pending office action. This suggests a narrow or early-stage prosecution strategy for the company's pharmaceutical interests.
Practitioners should focus exclusively on the preferences of NICKOL, GARY B to advance this case. The lack of multiple pending actions or examiners means there is no internal baseline for comparing prosecution success or examiner behavior. This company's strategy is currently tied to the resolution of this 1 pending office action. The outcome of this single case will define the current success of the patenting effort, making the interaction with the 1 distinct examiner the central element of the prosecution process. This singular focus within 1 art unit simplifies the administrative tracking but increases the impact of any single examiner's decision on the overall portfolio. The company must ensure that its responses are perfectly tailored to the expectations of this specific examiner to avoid further delays.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18436517 | METHOD FOR PROPHYLACTIC THERAPY OF CYTOKINE RELEASE SYNDROME AND/OR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) | NICKOL, GARY B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18436517 | METHOD FOR PROPHYLACTIC THERAPY OF CYTOKINE RELEASE SYNDROME AND/OR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) | NICKOL, GARY B | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18436517 | METHOD FOR PROPHYLACTIC THERAPY OF CYTOKINE RELEASE SYNDROME AND/OR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) | NICKOL, GARY B | 1643 | §102§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRecordati Rare Diseases Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gary B Nickol has the most, with 1 of Recordati Rare Diseases Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
